Is ATOSSA THERAPEUTICS, INC. (ATOS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 182.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.0% / 33% | 182.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 0.0% / 33% | 93.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 182.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 0.0% / 33% | 93.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -62.7% | |
| Return on Assets (ROA) | -37.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$21M |
| Free Cash Flow | -$21M |
| Current Ratio | 5.5 |
| Total Assets | $76M |
Price & Trading
| Last Close | $4.71 |
| 50-Day MA | $5.80 |
| 200-Day MA | $10.70 |
| Avg Volume | 146K |
|
52-Week Range
$3.76
| |
About ATOSSA THERAPEUTICS, INC. (ATOS)
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ATOSSA THERAPEUTICS, INC. (ATOS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ATOSSA THERAPEUTICS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ATOSSA THERAPEUTICS, INC.'s debt ratio?
ATOSSA THERAPEUTICS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are ATOSSA THERAPEUTICS, INC.'s key financial metrics?
ATOSSA THERAPEUTICS, INC. has a market capitalization of $41M. Return on equity stands at -62.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.